Gaucher Disease Drug Pipeline — PatSnap Eureka
Gaucher Disease Drug Pipeline: Oral SRT and Next-Generation ERT
GBA1 mutations drive glucosylceramide accumulation across macrophages and the reticuloendothelial system. Explore the patent landscape spanning oral glucosylceramide synthase inhibitors, pharmacological chaperones, hyperphosphorylated enzyme replacement, and biomarker-guided treatment strategies — all mapped through PatSnap Eureka.
GBA1 Mutations, GCase Deficiency, and the Lysosomal Substrate Cascade
Gaucher disease (GD) is the most prevalent lysosomal storage disorder (LSD). It results from mutations in the GBA1 gene encoding glucocerebrosidase (GCase), a lysosomal hydrolase that cleaves the beta-glucosidic bond of glucosylceramide (GlcCer). Deficiency causes substrate accumulation in lysosomes of macrophages, giving rise to the characteristic "Gaucher cell" and systemic disease manifestations.
Unlike most lysosomal hydrolases, GCase is not efficiently targeted to the lysosome via the canonical mannose-6-phosphate (M6P) receptor pathway. Instead, mannose receptor–mediated endocytosis by macrophages is the dominant uptake mechanism for current enzyme replacement therapies. This distinction, confirmed in patents from Novazyme Pharmaceuticals and Genzyme Glycobiology Research Institute, drives the engineering effort around the phosphorylation and glycosylation state of recombinant GCase molecules.
A secondary molecular pathology identified by Asan Medical Center (2022) involves accumulation of glucosylsphingosine (Lyso-Gb1) — the deacylated form of GlcCer — which is associated with complement dysregulation, autophagy disruption, macrophage polarization changes, TGF-β signaling alterations, and endothelial-to-mesenchymal transition (EndMT) leading to fibrosis. This multimodal pathology is the scientific basis for ERT non-responsiveness in atypical GD and highlights the need for multi-target therapeutic strategies.
A patent from Centogene AG positions Lyso-Gb1 as a validated druggable target relevant for both GD and Parkinson disease, which shares GBA1 haploinsufficiency as a risk factor. A separate Genzyme Corporation patent (CN, 2025) identifies CD63 plasma levels as a biomarker for lysosomal dysfunction and Gaucher disease progression, with utility for guiding treatment selection among SRT agents or ERT.
Four Converging Approaches in the Gaucher Disease Drug Pipeline
Patent analysis reveals distinct mechanistic strategies targeting GCase activity, GlcCer synthesis, protein homeostasis, and lysosomal biomarkers — each with a different IP landscape and development stage.
Substrate Reduction Therapy (SRT) — GCS Inhibitors
Small molecule inhibitors of glucosylceramide synthase (GCS) reduce the flux of glucosylceramide synthesis, alleviating lysosomal substrate burden. Miglustat (NB-DNJ) received conditional marketing authorization in Europe and the United States for type 1 GD — the first SRT approval in the disease space. Multiple Genzyme patent families (CN, 2014–2016) cover structurally distinct GCS inhibitor series for GD and other LSDs, with claims of use as monotherapy and in combination with ERT. BioMarin Pharmaceutical (CN, 2018) covers an additional scaffold with improved selectivity over miglustat. Eliglustat and venglustat are named as active SRT treatment options in the Genzyme CD63 biomarker patent (2025).
Miglustat approved · Eliglustat & venglustat named in IPPharmacological Chaperone Therapy
Small molecule competitive inhibitors of GCase, at sub-inhibitory concentrations, stabilize misfolded mutant GCase in the endoplasmic reticulum, facilitating proper trafficking to the lysosome and restoring residual enzymatic activity. This modality is applicable primarily to missense mutations producing misfolded but catalytically competent enzyme. Three distinct structural approaches are covered: iminosugar/isofagomine chaperones (Mount Sinai, 2006), GIZ/PHCA derivatives (Amicus Therapeutics, 2007), and arimoclomol — a hydroxylamine derivative amplifying HSP70/HSP90 protein quality control (Orphazyme/KemPharm/Zevra, 2021–2024 across AU, CA, IN).
Arimoclomol active across 3 jurisdictions · HSP amplification mechanismNext-Generation Enzyme Replacement Therapy (ERT)
Recombinant GCase is administered intravenously; uptake is mediated via mannose receptors on macrophages recognizing high-mannose glycans. Three engineering approaches are covered in retrieved patents: hyperphosphorylated GCase with M6P residues for improved lysosomal targeting (Novazyme/Genzyme, 2003); plant-cell-derived high-mannose GCase from transgenic carrot cell suspension cultures that bypasses costly post-production glycan remodeling (Protalix Biotherapeutics, 2011); and engineered GCase protein variants with modified properties beyond glycan optimization (Yeda Research, 2020). Imiglucerase is named as established ERT in the Genzyme biomarker patent.
Plant-derived GCase (taliglucerase alfa) · Hyperphosphorylated variantsBiomarker-Guided Treatment & Novel Target Axes
The Genzyme CD63 biomarker patent (CN, 2025) signals a move toward quantitative plasma biomarker-driven treatment decisions — selecting among SRT agents or ERT based on measured lysosomal dysfunction severity. Separately, the Centogene Lyso-Gb1 patent (CN, 2022) identifies the deacylated sphingolipid as a druggable target in its own right — relevant for neurological GD types where ERT is ineffective and for Parkinson disease with GBA1 mutations. Yeda Research holds a computational method patent (IL, 2012) using 3D structural coordinates of wild-type vs. mutant GCase to identify corrective compounds.
CD63 companion diagnostic · Lyso-Gb1 antagonism · GD + Parkinson relevancePatent Landscape Data: Assignees and Modality Distribution
Visualizing patent filing activity across key assignees and therapeutic modalities in the Gaucher disease innovation dataset retrieved via PatSnap Eureka.
Key Assignees by Retrieved Patent Families
Genzyme/Sanofi leads with 6 patent families spanning SRT, ERT, and diagnostics; Orphazyme/KemPharm/Zevra holds 3 families for arimoclomol across multiple jurisdictions.
Patent Filing Activity Over Time by Modality
Filing activity spans 2003 to 2025, with SRT filings concentrated 2007–2018, and chaperone/biomarker filings accelerating from 2021 onward.
Combination Approaches and Strategic Innovation Signals
Retrieved patent data signal deliberate co-development positioning across modalities and novel target axes that could reshape the GD treatment paradigm.
SRT + ERT Combination Strategy
Multiple Genzyme GCS inhibitor patents explicitly state that GCS inhibitors "can be used alone or in combination with enzyme replacement therapy." This co-development positioning reflects a deliberate IP strategy addressing differential tissue accessibility: ERT for systemic macrophage clearance; SRT for CNS-accessible substrate reduction.
Chaperone + ERT Combination Paradigm
The Asan Medical Center literature record highlights ambroxol as a chaperone that may potentiate ERT response in atypical GD by correcting misfolded GCase and improving lysosomal enzyme homeostasis. The Amicus Therapeutics pharmacological chaperone model for Pompe disease (AT2221 co-administered with recombinant GAA) provides a validated cross-indication precedent for this strategy.
Key Patent Holders in the Gaucher Disease Innovation Landscape
Commercial biopharma entities dominate this dataset. Genzyme Corporation (Sanofi) is the most active assignee, spanning SRT, ERT, and diagnostic domains.
| Assignee | Modality Focus | Jurisdictions | Filing Period | Key Asset |
|---|---|---|---|---|
| Genzyme Corporation (Sanofi) | SRT, ERT, Diagnostics | CN, WO, AU | 2003–2025 | GCS inhibitor series; CD63 biomarker patent; hyperphosphorylated GCase |
| Orphazyme / KemPharm / Zevra Denmark | Pharmacological Chaperone | AU, CA, IN | 2021–2024 | Arimoclomol (HSP70/HSP90 amplifier) for GD across 3 jurisdictions |
| Yeda Research & Development (Weizmann) | Computational Drug Discovery, ERT Engineering | IL | 2012, 2020 | 3D structural GCase compound ID method; GCase protein variants |
| Novazyme Pharmaceuticals (acq. Genzyme) | Next-Gen ERT | US | 2003 | Highly phosphorylated acid beta-glucocerebrosidase |
| Amicus Therapeutics | Pharmacological Chaperone, SRT | CN | 2007 | GIZ/PHCA derivatives as GCase chaperones; cross-LSD platform expertise |
| Protalix Biotherapeutics | Plant-Derived ERT | CN | 2011 | High-mannose GCase from transgenic carrot cell suspension cultures |
| BioMarin Pharmaceutical | SRT (Next-Gen GCS Inhibitor) | CN | 2018 | Novel GCS inhibitor scaffold with improved selectivity over miglustat |
| Centogene AG | Biomarker / Novel Target | CN | 2022 | Lyso-Gb1 as druggable target in GD and Parkinson disease |
Screen Competitors Across the Full GBA1 Patent Space
Use PatSnap Eureka's IP analytics platform to benchmark assignees, track filing velocity, and identify white-space opportunities.
Clinical and Translational Signals from the Patent Dataset
Retrieved results contain limited but meaningful signals of clinical translation. Miglustat (NB-DNJ, SRT) is confirmed as approved: the Amicus Therapeutics patent (CN, 2007) and Genzyme GCS inhibitor patents both reference miglustat's conditional marketing authorization in Europe and the United States for type 1 GD as prior art, confirming clinical validation of the GCS inhibition mechanism.
Eliglustat and venglustat are named as active treatments in the Genzyme CD63 biomarker patent (CN, 2025), which explicitly names venglustat, eliglustat, and miglustat as treatment options to be administered when CD63 exceeds a control threshold, alongside ERT (imiglucerase). This filing implies at least clinical-stage or commercial status for all three agents at the time of filing.
Ambroxol as a chemical chaperone carries a clinical signal from academic literature: the Asan Medical Center record (2022) describes ambroxol's "potential therapeutic role" as a chemical chaperone in GD, specifically highlighting multi-functional therapeutic approaches for atypical GD cases with ERT non-responsiveness. The clinical trial context for ambroxol in GD represents a translational signal from clinical observation.
Arimoclomol shows an active patent portfolio across multiple jurisdictions: patent filings in IN, AU, and CA are active or pending (2021–2024), suggesting ongoing clinical development rather than preclinical discovery. The description of "improved methods" in the CA filing implies iterative clinical protocol optimization. For broader LSD pipeline context, PatSnap's life sciences intelligence platform enables cross-indication tracking across lysosomal storage disorders.
Note: No clinical trial data, efficacy endpoints, or regulatory submission details are directly described in retrieved results; clinical translation is inferred from patent filing context and named drug references. This dataset represents a snapshot of innovation signals only.
IP Strategy and Competitive Implications for Pipeline Teams
Key strategic signals for R&D, IP, and business development teams working in the Gaucher disease and broader lysosomal storage disorder space.
Oral GCS Inhibition: Layered IP Environment Constrains Structural Novelty
GCS inhibition (SRT) is the dominant oral modality, with approved agents (miglustat) and clinically advanced successors (eliglustat, venglustat) already named in the IP landscape. New entrant GCS inhibitor scaffolds must offer significant differentiation in selectivity, CNS penetration, or pharmacokinetic profile to compete. The BioMarin and Genzyme patent families create a layered IP environment that may constrain structural novelty for new entrants.
Differentiation required on CNS penetration or selectivityGlycoengineering of Recombinant GCase Remains an Active and Defensible Space
The hyperphosphorylated GCase and plant-derived high-mannose GCase patents demonstrate two distinct manufacturing strategies. IP around M6P content, glycan profile, and uptake efficiency is still being filed, representing a competitive opportunity for biosimilar and next-generation ERT developers. The Yeda Research GCase variant patent (IL, 2020, pending) signals exploration of protein sequence-level engineering beyond glycan optimization — potentially enabling GCase molecules with improved CNS penetration.
M6P content, glycan profile, and protein engineering all activeGaucher Disease Drug Pipeline — Key Questions Answered
Gaucher disease (GD) is the most prevalent lysosomal storage disorder (LSD). It results from mutations in the GBA1 gene encoding glucocerebrosidase (GCase), leading to pathological accumulation of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph/Lyso-Gb1) primarily in macrophages and the reticuloendothelial system.
Substrate reduction therapy uses small molecule inhibitors of glucosylceramide synthase (GCS) to reduce the flux of glucosylceramide synthesis, thereby alleviating lysosomal substrate burden. Miglustat received conditional marketing authorization in Europe and the United States for type 1 GD, constituting the first SRT approval in the disease space. Eliglustat and venglustat are named as additional active SRT treatment options.
Small molecule competitive inhibitors of GCase, when administered at sub-inhibitory concentrations, stabilize misfolded mutant GCase in the endoplasmic reticulum, facilitating proper trafficking to the lysosome and restoring residual enzymatic activity. This modality is genotype-restricted, applicable primarily to missense mutations producing misfolded but catalytically competent enzyme.
Lyso-Gb1 (glucosylsphingosine) accumulation is associated with complement dysregulation, autophagy disruption, macrophage polarization changes, TGF-β signaling alterations, and endothelial-to-mesenchymal transition (EndMT) leading to fibrosis. This multimodal pathology is the scientific basis for ERT non-responsiveness in atypical GD. A Centogene patent positions Lyso-Gb1 as a validated druggable target relevant for both GD and Parkinson disease.
Arimoclomol is a hydroxylamine derivative that co-induces heat shock proteins (HSPs). Its mechanism involves amplifying the cellular protein quality control machinery (HSP70/HSP90) to rescue misfolded GCase. Multiple patents from Orphazyme A/S (now KemPharm Denmark A/S / Zevra Denmark A/S) across AU, CA, and IN jurisdictions (2021–2024) claim arimoclomol for treating GD, representing a distinct class of protein homeostasis modulator.
A Genzyme Corporation patent (CN, 2025) identifies CD63 plasma levels as a biomarker for lysosomal dysfunction and Gaucher disease progression, with utility for guiding treatment selection among SRT agents (venglustat, eliglustat, miglustat) or ERT (imiglucerase). Elevated plasma CD63 levels can trigger initiation of therapy, positioning CD63 as a companion diagnostic tool for treatment decisions.
Still have questions about the Gaucher disease patent landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About GBA1Accelerate Your Gaucher Disease Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map GBA1 patent landscapes, track competitor filings, and identify white-space opportunities in lysosomal storage disorders.
References
- Gaucher Disease Drugs and Methods of Identifying Same — Yeda Research and Development Co. Ltd., 2012, IL [Patent]
- Glucosylceramide Synthase Inhibitors (2014 filing) — Genzyme Corporation, 2014, CN [Patent]
- Glucosylceramide Synthase Inhibitors (2016 filing) — Genzyme Corporation, 2016, CN [Patent]
- Glucocerebroside Synthase Inhibitors (2015 filing) — Genzyme Corporation, 2015, CN [Patent]
- Glucosylceramide Synthase Inhibitor for Treating Disease — BioMarin Pharmaceutical Inc., 2018, CN [Patent]
- Glucoimidazole and Polyhydroxycyclohexylamines Derivatives for Treating Gaucher Disease — Amicus Therapeutics, 2007, CN [Patent]
- Highly Phosphorylated Acid Beta-Glucocerebrosidase — Novazyme Pharmaceuticals, Inc., 2003, US [Patent]
- Highly Phosphorylated Acid Beta-Glucocerebrosidase — Genzyme Glycobiology Research Institute Inc., 2003, AU [Patent]
- Highly Phosphorylated Acid Beta-Glucocerebrosidase — Genzyme Glycobiology Research Institute, Inc., 2003, WO [Patent]
- Production of High-Mannose Proteins Using Plant Culture — Protalix Biotherapeutics, 2011, CN [Patent]
- Variants of Beta-Glucocerebrosidase for Use in Treating Gaucher Disease — Yeda Research and Development Co. Ltd., 2020, IL [Patent]
- Method for Enhancing Mutant Enzyme Activities in Gaucher Disease — Mount Sinai School of Medicine of New York University, 2006, US [Patent]
- Arimoclomol for Treating Gaucher Disease — KemPharm Denmark A/S, 2021, CA [Patent]
- Arimoclomol for Treating Gaucher Disease — Orphazyme A/S, 2023, AU [Patent]
- Arimoclomol for Treating Gaucher Disease — Zevra Denmark A/S, 2024, IN [Patent]
- Methods and Kits for Diagnosing and/or Assessing Severity and Treating Gaucher Disease — Ron Ronen, Idit, 2005, WO [Patent]
- Use of Lyso-Gb1 as a Druggable Target — Centogene AG, 2022, CN [Patent]
- Biomarkers of Lysosomal Storage Disease — Genzyme Corporation, 2025, CN [Patent]
- Identification of a Novel Therapeutic Target Underlying Atypical Manifestation of Gaucher Disease — Asan Institute for Life Sciences, Asan Medical Center, Seoul, 2022 [Paper]
- Gaucher Disease — MedlinePlus / National Library of Medicine [External]
- ClinicalTrials.gov — U.S. National Library of Medicine [External]
- Parkinson's Foundation — GBA1 and Parkinson Disease Genetics [External]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent records retrieved via PatSnap Eureka. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.